Cargando…

Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE

BACKGROUND: Hereditary thrombocytopenias constitute a genetically heterogeneous cause of increased bleeding. We report a case of a 17-year-old boy suffering from severe macrothrombocytopenia throughout his life. Whole genome sequencing revealed the presence of two compound heterozygous variants in G...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolag, Karolina I., Fager Ferrari, Marcus, Zetterberg, Eva, Leinoe, Eva, Ek, Torben, Blom, Anna M., Rossing, Maria, Martin, Myriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630651/
https://www.ncbi.nlm.nih.gov/pubmed/34858435
http://dx.doi.org/10.3389/fimmu.2021.777402
_version_ 1784607404228345856
author Smolag, Karolina I.
Fager Ferrari, Marcus
Zetterberg, Eva
Leinoe, Eva
Ek, Torben
Blom, Anna M.
Rossing, Maria
Martin, Myriam
author_facet Smolag, Karolina I.
Fager Ferrari, Marcus
Zetterberg, Eva
Leinoe, Eva
Ek, Torben
Blom, Anna M.
Rossing, Maria
Martin, Myriam
author_sort Smolag, Karolina I.
collection PubMed
description BACKGROUND: Hereditary thrombocytopenias constitute a genetically heterogeneous cause of increased bleeding. We report a case of a 17-year-old boy suffering from severe macrothrombocytopenia throughout his life. Whole genome sequencing revealed the presence of two compound heterozygous variants in GNE encoding the enzyme UDP-N-acetyl-glucosamine-2-epimerase/N-acetylmannosamine kinase, crucial for sialic acid biosynthesis. Sialic acid is required for normal platelet life span, and biallelic variants in GNE have previously been associated with isolated macrothrombocytopenia. Furthermore, sialic acid constitutes a key ligand for complement factor H (FH), an important inhibitor of the complement system, protecting host cells from indiscriminate attack. METHODS: Sialic acid expression and FH binding to platelets and leukocytes was evaluated by flow cytometry. The binding of FH to erythrocytes was assessed indirectly by measuring the rate of complement mediated hemolysis. Complement activation was determined by measuring levels of C3bBbP (alternative pathway), C4d (classical/lectin pathway) and soluble terminal complement complex assays. RESULTS: The proband exhibited markedly decreased expression of sialic acid on platelets and leukocytes. Consequently, the binding of FH was strongly reduced and moderate activation of the alternative and classical/lectin complement pathways was observed, together with an increased rate of erythrocyte lysis. CONCLUSION: We report two previously undescribed variants in GNE causing severe congenital macrothrombocytopenia in a compound heterozygous state, as a consequence of decreased platelet sialylation. The decreased sialylation of platelets, leukocytes and erythrocytes affects the binding of FH, leading to moderate complement activation and increased hemolysis.
format Online
Article
Text
id pubmed-8630651
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86306512021-12-01 Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE Smolag, Karolina I. Fager Ferrari, Marcus Zetterberg, Eva Leinoe, Eva Ek, Torben Blom, Anna M. Rossing, Maria Martin, Myriam Front Immunol Immunology BACKGROUND: Hereditary thrombocytopenias constitute a genetically heterogeneous cause of increased bleeding. We report a case of a 17-year-old boy suffering from severe macrothrombocytopenia throughout his life. Whole genome sequencing revealed the presence of two compound heterozygous variants in GNE encoding the enzyme UDP-N-acetyl-glucosamine-2-epimerase/N-acetylmannosamine kinase, crucial for sialic acid biosynthesis. Sialic acid is required for normal platelet life span, and biallelic variants in GNE have previously been associated with isolated macrothrombocytopenia. Furthermore, sialic acid constitutes a key ligand for complement factor H (FH), an important inhibitor of the complement system, protecting host cells from indiscriminate attack. METHODS: Sialic acid expression and FH binding to platelets and leukocytes was evaluated by flow cytometry. The binding of FH to erythrocytes was assessed indirectly by measuring the rate of complement mediated hemolysis. Complement activation was determined by measuring levels of C3bBbP (alternative pathway), C4d (classical/lectin pathway) and soluble terminal complement complex assays. RESULTS: The proband exhibited markedly decreased expression of sialic acid on platelets and leukocytes. Consequently, the binding of FH was strongly reduced and moderate activation of the alternative and classical/lectin complement pathways was observed, together with an increased rate of erythrocyte lysis. CONCLUSION: We report two previously undescribed variants in GNE causing severe congenital macrothrombocytopenia in a compound heterozygous state, as a consequence of decreased platelet sialylation. The decreased sialylation of platelets, leukocytes and erythrocytes affects the binding of FH, leading to moderate complement activation and increased hemolysis. Frontiers Media S.A. 2021-11-09 /pmc/articles/PMC8630651/ /pubmed/34858435 http://dx.doi.org/10.3389/fimmu.2021.777402 Text en Copyright © 2021 Smolag, Fager Ferrari, Zetterberg, Leinoe, Ek, Blom, Rossing and Martin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Smolag, Karolina I.
Fager Ferrari, Marcus
Zetterberg, Eva
Leinoe, Eva
Ek, Torben
Blom, Anna M.
Rossing, Maria
Martin, Myriam
Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE
title Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE
title_full Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE
title_fullStr Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE
title_full_unstemmed Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE
title_short Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE
title_sort severe congenital thrombocytopenia characterized by decreased platelet sialylation and moderate complement activation caused by novel compound heterozygous variants in gne
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630651/
https://www.ncbi.nlm.nih.gov/pubmed/34858435
http://dx.doi.org/10.3389/fimmu.2021.777402
work_keys_str_mv AT smolagkarolinai severecongenitalthrombocytopeniacharacterizedbydecreasedplateletsialylationandmoderatecomplementactivationcausedbynovelcompoundheterozygousvariantsingne
AT fagerferrarimarcus severecongenitalthrombocytopeniacharacterizedbydecreasedplateletsialylationandmoderatecomplementactivationcausedbynovelcompoundheterozygousvariantsingne
AT zetterbergeva severecongenitalthrombocytopeniacharacterizedbydecreasedplateletsialylationandmoderatecomplementactivationcausedbynovelcompoundheterozygousvariantsingne
AT leinoeeva severecongenitalthrombocytopeniacharacterizedbydecreasedplateletsialylationandmoderatecomplementactivationcausedbynovelcompoundheterozygousvariantsingne
AT ektorben severecongenitalthrombocytopeniacharacterizedbydecreasedplateletsialylationandmoderatecomplementactivationcausedbynovelcompoundheterozygousvariantsingne
AT blomannam severecongenitalthrombocytopeniacharacterizedbydecreasedplateletsialylationandmoderatecomplementactivationcausedbynovelcompoundheterozygousvariantsingne
AT rossingmaria severecongenitalthrombocytopeniacharacterizedbydecreasedplateletsialylationandmoderatecomplementactivationcausedbynovelcompoundheterozygousvariantsingne
AT martinmyriam severecongenitalthrombocytopeniacharacterizedbydecreasedplateletsialylationandmoderatecomplementactivationcausedbynovelcompoundheterozygousvariantsingne